Overview
Retatrutide is a synthetic acylated peptide that functions as a triple agonist at three distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). It represents the next generation of incretin-based metabolic research compounds, building on the dual GIP/GLP-1 agonist framework by adding glucagon receptor co-activation. This triple mechanism is designed to engage complementary and partially non-overlapping metabolic pathways simultaneously, with the glucagon receptor component contributing additional effects on hepatic glucose output, energy expenditure, and lipid oxidation that are not accessible through GIP and GLP-1 receptor agonism alone.
Mechanism
Retatrutide's GLP-1R agonism stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and engages central appetite circuits. Its GIPR agonism contributes additional insulin secretion, direct adipocyte effects, and potential synergy with GLP-1R signaling. The glucagon receptor component activates hepatic gluconeogenesis and glycogenolysis (relevant to glucose flux research), stimulates adipose tissue lipolysis, and increases energy expenditure through thermogenic mechanisms in brown adipose tissue. In research models, the net effect of glucagon receptor co-activation alongside GIP and GLP-1 receptor agonism is studied for its potential to drive greater reductions in adipose mass and improvements in metabolic parameters than dual agonism alone, without the hyperglycemic effects that pure glucagon receptor agonism would produce in isolation.
Research Areas
-
Triple Incretin Receptor Research
Retatrutide is used as a pharmacological tool to study the combined and individual contributions of GIP, GLP-1, and glucagon receptor signaling to metabolic outcomes in preclinical models.
-
Adipose Tissue & Energy Expenditure Research
Research has examined the glucagon receptor-mediated effects on brown adipose tissue thermogenesis, white adipose lipolysis, and overall energy expenditure in animal models.
-
Hepatic Metabolism Research
Studies have explored glucagon receptor co-activation and its effects on hepatic glucose output, lipid metabolism, and liver fat accumulation in metabolic research models.
-
Comparative Incretin Research
Retatrutide is studied alongside dual agonists (tirzepatide) and monoagonists (semaglutide) to characterize the incremental metabolic contributions of each receptor target in controlled research settings.
Storage
Store lyophilized at -20°C. Reconstitute with sterile bacteriostatic water. Once reconstituted, store at 4°C and use within 28 days. Protect from light and avoid repeated freeze-thaw cycles.